Výsledky vyhledávání

Introduction ATLAS compared bevacizumab plus erlotinib (B+E) with bevacizumab plus placebo (B+P) as maintenance therapy after first-line bevacizumab plus chemotherapy (B+C) for advanced non-small-cell lung cancer (NSCLC). Prespecified biomarkers were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c8181de9f37ca8c54b9983d676ae4d4
https://doi.org/10.1097/jto.0000000000000274

Zobrazit plný text záznamu

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

Autor: Max E. Scheulen, Chung-Pin Li, Ngocdiep Le, Joon Oh Park, Yuan Liu, Klaudia Steplewski, Saifuddin M. Kasubhai, Do-Youn Oh, Jeffrey R. Infante, Bradley G. Somer, Suman Redhu

Publikováno v: European journal of cancer (Oxford, England : 1990). 50(12)

Background Trametinib, an oral mitogen/extracellular signal-related kinase (MEK)1/2 inhibitor, holds promise for malignancies with rat sarcoma (RAS) mutations, like pancreas cancer. This phase II study was designed to determine overall survival (OS)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d544a6b63799615777921b384ed3118f
https://pubmed.ncbi.nlm.nih.gov/24915778

Zobrazit plný text záznamu

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer

Autor: Chris Bowden, Vincent A. Miller, Taral Patel, Leonard White, Fairooz F. Kabbinavar, Saifuddin M. Kasubhai, Bruce Kressel, Louis Fehrenbacher, Jonathan Polikoff, John D. Hainsworth, Thomas Marsland, Mark A. Rubin, Chin-Yu Lin, James Chih-Hsin Yang, Bruce E. Johnson

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(31)

Purpose This phase III trial was performed to assess the potential benefit of adding maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced non–small-cell lung cancer (NSCLC). Patients and Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e85fdd12807abfe636b7b2a73b26e432
https://pubmed.ncbi.nlm.nih.gov/24101054

Zobrazit plný text záznamu

A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors

Autor: Mohammed M. Dar, Lionel D. Lewis, Howard A. Ball, Thehang Luu, Jeffrey R. Infante, Bo Ma, Elisabeth I. Heath, Antoinette R. Tan, Patricia LoRusso, Saifuddin M. Kasubhai, Joe Stephenson, Joseph F. Kleha, A. Benjamin Suttle

Publikováno v: Cancer chemotherapy and pharmacology. 71(3)

As tyrosine kinase inhibitors have been associated with cardiotoxicity, we evaluated the effect of pazopanib, an inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit, on electrocardiographic par

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b9784d63753c2952ab4cf490e3a24f1
https://pubmed.ncbi.nlm.nih.gov/23344712

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání